The Global Biosimilars market fuel the growth of pharmaceutical industries owing to cost-effectiveness and active ingredients
The Global biosimilars market will anticipate a remarkable CAGR in the forecast period from 2020-2027. A high amount of investment done by the pharmaceutical sector in biosimilars is proving as an innovation in the pharmaceutical industry.
Moreover, the biosimilars are rapidly increasing their penetration in the field of immunological diseases and tumor treatment due to their advantages, such as better efficacy and lower side effects.
Furthermore, biosimilars are cost-effective and majorly used for curing chronic diseases, and they get secure permission for their application. Also, biosimilars are similar patent drugs in terms of safety, efficacy, and immunity. With ongoing funding from the government and investment in R&D has fueled the demand for the global biosimilars market.
Product Overview in the Global Biosimilars Market
Based on the product, the global biosimilars market segmented into Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin. The interferon segment has captured the highest market share in the global biosimilars market in the forecast period from 2020-2027. With the rising geriatric population and increasing chronic diseases, the interferon segment has dominated the biosimilars as they treat the cancers and other diseases in a cost-effective manner.
Manufacturing Overview in the Global Biosimilars Market
Based on the manufacturing, the global biosimilars market bifurcated into In-house, Contract. The in-house part has dominated the market share of the global biosimilars market. In-house manufacturing of biosimilars will help in the reduction of cost and keep every operational and another step-in check and overall reduce the value of the medicines.
Indication Overview in the Global Biosimilars Market
Based on the indication, the global biosimilars market segmented into Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease. The oncology segment has a significant market demand in the global biosimilars market. With rising, biosimilars demand oncology segment will help in curing cancer at minimal cost with the use of oncology.
Region Overview in the Global Biosimilars Market
Based on geography, the global biosimilars market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The European region is going to bolster the market growth of biosimilars in the global market in the forecast period from 2020-2027. Due to the rising obesity and increasing cases of cancer, diabetics and biosimilars will treat it economically. Therefore, the European region will fuel the market demand for the global biosimilar market.
Global Biosimilars Market: Competitive Landscape
Companies such Pfizer, Sandoz, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Amega Biotech, mAbxience, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, and Stada Arzneimittel AG and others are key players in the global biosimilars market.
Global Biosimilars Market Report Content 1. Research Strategic Development 1.1. Market Modelling 1.2. Product Analysis 1.3. Market Trend and Economic Factors Analysis 1.4. Market Segmental Analysis 1.5. Geographical Mapping 1.6. Country Wise Segregation 2. Research Methodology 2.1. Identification of Target Market 2.2. Data Acquisition 2.3. Refining of Data/ Data Transformations 2.4. Data Validation through Primary Techniques 2.5. Exploratory Data Analysis 2.6. Graphical Techniques/Analysis 2.7. Quantitative Techniques/Analysis 2.8. Visual Result/Presentation 3. Executive Summary 4. Market Insights 4.1. Economic Factor Analysis 4.1.1. Drivers 4.1.2. Trends 4.1.3. Opportunities 4.1.4. Challenges 4.2. Competitors & Product Analysis 4.3. Regulatory Framework 4.4. Company market share analysis, 2019 4.5. Porter's Five forces analysis 4.6. New Investment Analysis 4.7. PESTEL Analysis 5. Global Biosimilars Market Overview 5.1. Market Size & Forecast, 2016-2027 5.1.1. Demand 5.1.1.1. By Value (USD Million) 5.2. Market Share & Forecast, 2016-2027 5.2.1. By Product 5.2.1.1. Insulin 5.2.1.2. Interferon 5.2.1.3. Etanercept 5.2.1.4. Infliximab 5.2.1.5. Rituximab 5.2.1.6. Glucagon 5.2.1.7. Calcitonin 5.2.2. By Manufacturing 5.2.2.1. In-house 5.2.2.2. Contract 5.2.3. By Indication 5.2.3.1. Oncology 5.2.3.2. Chronic Disease 5.2.3.3. Blood Disorder 5.2.3.4. Autoimmune Disease 5.2.4. By Region 5.2.4.1. Europe 5.2.4.2. North America 5.2.4.3. Asia Pacific 5.2.4.4. South America 5.2.4.5. Middle East & Africa 6. Europe Biosimilars Market Overview 6.1. Europe Biosimilars Size & Forecast, 2016-2027 6.1.1. Demand 6.1.1.1. By Value (USD Million) 6.2. Europe Biosimilars Market Share & Forecast, 2016-2027 6.2.1. By Product 6.2.1.1. Insulin 6.2.1.2. Interferon 6.2.1.3. Etanercept 6.2.1.4. Infliximab 6.2.1.5. Rituximab 6.2.1.6. Glucagon 6.2.1.7. Calcitonin 6.2.2. By Manufacturing 6.2.2.1. In-house 6.2.2.2. Contract 6.2.3. By Indication 6.2.3.1. Oncology 6.2.3.2. Chronic Disease 6.2.3.3. Blood Disorder 6.2.3.4. Autoimmune Disease 6.2.4. By Country 6.2.4.1. Germany 6.2.4.2. UK 6.2.4.3. France 6.2.4.4. Italy 6.2.4.5. Rest of Europe 6.2.5. Company Market Share (Top 3-5) 6.2.6. Economic Impact Study on Europe Biosimilars Market 7. North America Biosimilars Market Overview 7.1. North America Biosimilars Market Size & Forecast, 2016-2027 7.1.1. Demand 7.1.1.1. By Value (USD Million) 7.2. North America Biosimilars Market Share & Forecast, 2016-2027 7.2.1. By Product 7.2.1.1. Insulin 7.2.1.2. Interferon 7.2.1.3. Etanercept 7.2.1.4. Infliximab 7.2.1.5. Rituximab 7.2.1.6. Glucagon 7.2.1.7. Calcitonin 7.2.2. By Manufacturing 7.2.2.1. In-house 7.2.2.2. Contract 7.2.3. By Indication 7.2.3.1. Oncology 7.2.3.2. Chronic Disease 7.2.3.3. Blood Disorder 7.2.3.4. Autoimmune Disease 7.2.4. By Country 7.2.4.1. US 7.2.4.2. Canada 7.2.4.3. Mexico 7.2.5. Company Market Share (Top 3-5) 7.2.6. Economic Impact Study on North America Biosimilars Market 8. Asia Pacific Biosimilars Overview 8.1. Asia Pacific Biosimilars Market Size & Forecast, 2016-2027 8.1.1. Demand 8.1.1.1. By Value (USD Million) 8.2. Asia Pacific Biosimilars Market Share & Forecast, 2016-2027 8.2.1. By Product 8.2.1.1. Insulin 8.2.1.2. Interferon 8.2.1.3. Etanercept 8.2.1.4. Infliximab 8.2.1.5. Rituximab 8.2.1.6. Glucagon 8.2.1.7. Calcitonin 8.2.2. By Manufacturing 8.2.2.1. In-house 8.2.2.2. Contract 8.2.3. By Indication 8.2.3.1. Oncology 8.2.3.2. Chronic Disease 8.2.3.3. Blood Disorder 8.2.3.4. Autoimmune Disease 8.2.4. By Country 8.2.4.1. China 8.2.4.2. India 8.2.4.3. Japan 8.2.4.4. Australia 8.2.4.5. Rest of Asia Pacific 8.2.5. Company Market Share (Top 3-5) 8.2.6. Economic Impact Study on Asia Pacific Biosimilars Market 9. South America Biosimilars Market Overview 9.1. South America Biosimilars Market Size & Forecast, 2016-2027 9.1.1. Demand 9.1.1.1. By Value (USD Million) 9.2. South America Biosimilars Market Share & Forecast, 2016-2027 9.2.1. By Product 9.2.1.1. Insulin 9.2.1.2. Interferon 9.2.1.3. Etanercept 9.2.1.4. Infliximab 9.2.1.5. Rituximab 9.2.1.6. Glucagon 9.2.1.7. Calcitonin 9.2.2. By Manufacturing 9.2.2.1. In-house 9.2.2.2. Contract 9.2.3. By Indication 9.2.3.1. Oncology 9.2.3.2. Chronic Disease 9.2.3.3. Blood Disorder 9.2.3.4. Autoimmune Disease 9.2.4. By Country 9.2.4.1. Brazil 9.2.4.2. Argentina 9.2.4.3. Rest of South America 9.2.5. Company Market Share (Top 3-5) 9.2.6. Economic Impact Study on South America Biosimilars Market 10. Middle East & Africa Biosimilars Market Overview 10.1. Middle East & Africa Biosimilars Market Size & Forecast, 2016-2027 10.1.1. Demand 10.1.1.1. By Value (USD Million) 10.2. Middle East & Africa Biosimilars Market Share & Forecast, 2016-2027 10.2.1. By Product 10.2.1.1. Insulin 10.2.1.2. Interferon 10.2.1.3. Etanercept 10.2.1.4. Infliximab 10.2.1.5. Rituximab 10.2.1.6. Glucagon 10.2.1.7. Calcitonin 10.2.2. By Manufacturing 10.2.2.1. In-house 10.2.2.2. Contract 10.2.3. By Indication 10.2.3.1. Oncology 10.2.3.2. Chronic Disease 10.2.3.3. Blood Disorder 10.2.3.4. Autoimmune Disease 10.2.4. By Country 10.2.4.1. Saudi Arabia 10.2.4.2. UAE 10.2.4.3. South Africa 10.2.4.4. Rest of Middle East & Africa 10.2.5. Company Market Share (Top 3-5) 10.2.6. Economic Impact Study on Middle East & Africa Biosimilars Market 11. Competitor Analysis 11.1. Company Description 11.2. Financial Analysis 11.3. Key Products 11.4. Key Management Personnel 11.5. Contact Address 11.6. SWOT Analysis 11.7. Company Profile 11.7.1. Pfizer 11.7.2. Sandoz 11.7.3. Biocon 11.7.4. Fresenius Kabi AG 11.7.5. Boehringer Ingelheim 11.7.6. Mylan 11.7.7. Eli Lilly 11.7.8. Teva Pharmaceutical 11.7.9. Dr. Reddy's Laboratories 11.7.10. Amgen 11.7.11. Celltrion 11.7.12. Samsung Biologics 11.7.13. Amega Biotech 11.7.14. mAbxience 11.7.15. Probiomed 11.7.16. Apotex 11.7.17. Gedeon Richter 11.7.18. Biocad 11.7.19. Coherus Bioscience 11.7.20. Stada Arzneimittel AG 11.7.21. Other Prominent Players
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 114 |
| Price : US$ 2400 | Date : Jan 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 133 |
| Price : US$ 2400 | Date : Jan 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 133 |
| Price : US$ 2400 | Date : Jan 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 126 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
